News

Submission of the MAA for Xilonix is necessary for the Company to gain approval to sell the drug in European Union member nations. The Company, which only recently

Proceeds will be used to advance the company’s immunotherapy programs. These programs include its lead drug candidate, an anti-CCR4 monoclonal antibody for the treatment of cancer, which is

The company expects to report top-line data from the study in the third quarter of this year. Under the phase 2 ReVEAL study, the company will assess the

The trial was a pivotal Phase 2/3 study designed to evaluate KEYTRUDA compared to chemotherapy based on prospective measurement of PD-L1 expression in previously treated patients with advanced

"CDI results from damage to the microbiome, and patients experience further collateral damage through the use of broad spectrum antibiotics to treat CDI, leaving them vulnerable to recurrent

The Company also announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with Systemic Lupus Erythematosus (SLE). "We are advancing XmAb5871 in IgG4-RD

The agreement covers the compound BI655066, an anti-IL-23 monoclonal biologic antibody in Phase 3 development for psoriasis. BI 655066 selectively blocks IL-23, a key protein involved in skin

Rintega (rindopepimut) is an investigational immunotherapy that targets the tumor specific oncogene EGFRvIII, a functional and permanently activated mutation of the epidermal growth factor receptor (EGFR) which has

Two doses of the drug were tested against a placebo and an oral antiviral called ribavarin to evaluate their effect on survival of immune-deficient mice infected with Zika